November 8, 2021 -- Asuragen, a Bio-Techne brand, has launched a new test kit to detect pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
The AmplideX PCR/CE CFTR Kit, which is intended for research use only, delivers results in less than five hours. It is designed to detect approximately 93% of CFTR pathogenic variants observed in the U.S. population. It can also identify a broad range of variant types, including copy number variants; single tandem repeats; and single nucleotide polymorphisms, insertions, and deletions. The kit can resolve variant zygosity.
Furthermore, it is optimized for use on polymerase chain reaction (PCR) and capillary electrophoresis laboratory equipment, and the kit can be combined with Asuragen's AmplideX PCR/CE FMR1 Kit and the SMN1/2 Plus Kit to provide the same-platform assay for this trio of the most prevalent and commonly analyzed carrier genes.